Latest Conference Articles

Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.

Patients with previously untreated HLA-A*02:01+ mUM saw improvements in OS, PFS, and ctDNA clearance.

Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.

According to investigators, additional research is necessary to further understand how lutetium impacts overall survival in patients with metastatic prostate cancer.

The trial data showed ongoing clinical benefit in patients with advanced endometrial cancer who completed pembrolizumab and continued on lenvatinib vs chemotherapy alone.

Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.

This is the first phase 3 trial to evaluate a KRAS G12C-inhibitor plus an anti-epidermal growth factor receptor antibody for this type of colorectal cancer.

The novel combination met the co-primary endpoints of progression-free survival and overall survival during the CheckMate -901 trial, also demonstrating sizeable improvement in objective response.

Oncology leaders and pharma representatives discuss collaboration best practices.

Compared to endocrine therapy alone, the combination of ribociclib and endocrine therapy lowered the risk of cancer recurrence in patients with early breast cancer by 25.2%.

Saira A. Jan, MS, PharmD, discussed a novel pilot program in New Jersey aiming to expand home infusion services in oncology.

The statistically significant and clinically meaningful improvement in disease-free survival is “practice-changing” and may represent a “paradigm shift” in treatment, according to experts.

Timothy O’Shea, MS, PharmD, discussed the growth of home infusion programs and how they benefit patients.

Kimberly Maxfield, PhD, discussed pharmacist’s role to aid patients when switching to a biosimilar

Among individuals who received systemic antibiotics within 8 weeks, 6 months, 12 months, and 24 months of receiving fecal microbiota, RBX2660 prevented recurrence.

Biosimilars in the pharmacy benefit are as effective as their reference drug, but it’s important for the pharmacist to clarify this to patients.

The biosimilar landscape is growing, but the FDA should leverage analytical data to efficiently determine the quality of these products and propel them toward approval, according to a session at the Academy of Managed Care Pharmacy’s Nexus 2023 conference.

Approximately 96% physicians feel it is important to assess patients aged 60 years and older for cognitive impairment, but 48% of these patients have no had assessments from their physician.

The FDA is the only authority that can designate a biosimilar as interchangeable with its reference product, which requires that the product has similar clinical results for the same indication.

There are 3 main medication-related issues for mental health care, which includes polypharmacy, nonadherence to prescribed medication, and underutilization of medications.

Areas of focus for specialty medications include biosimilars, cancer treatments, and drugs across disease states such as inflammatory conditions, HIV, and multiple sclerosis.

Jensen notes that although she expects there will be a lot of FDA approvals in 2023 and 2024, there likely will not be another biosimilar “boom” until 2025.

Jeff J, Mclntyre, MA, Vice President of Liver Health Programs, Global Liver Institute, discussed the clinical and economic burden of NASH

Artificial intelligence and machine learning can significantly benefit managed care pharmacy, specifically in contract reading and interpretation.

Obesity is a chronic disease comprised of dysregulated adipose tissue, increasing the risk of developing serious health conditions, and requires more than just losing weight.

In a recent study, 97% of patients had to wait a day before receiving their prescription, and this may worsen the risk of hospitalization.

Reform efforts to consider how health care plans may capitalize on disclosures, balancing out-of-pocket spending access, and how pharmacists can help plan members with the increased transparency of pharmacy benefit managers.

These pharmacies can use electronic medical records to work more directly with providers, monitoring adverse medication effects and assessment schedules and being more tuned into patient needs.